In order to find whether the IL1R2 neutralizing antibody treatment in vivo decreases the BTIC population in xenograft tumors, the single BC cells from primary xenograft tumors with the treatment were then isolated and implanted to nude mice for a secondary xenograft tumor formation assay without treatment. The gene discussed is IL1R2; the disease is breast cancer.